

THE TRINITY FOUNDER'S COLLECTION



VOLUME II

Building the Trinity Ecosystem

A founder's operating blueprint for distinct companies, disciplined leadership,
responsible growth, and institutional continuity

MIDPOINT COLLECTOR'S REVIEW EDITION

FRONT MATTER • CHAPTERS 1-15 • PORTFOLIO INSERT • RESPONSIBILITY MATRIX

ABEL ORTIZ • GABRIEL • CRISTINA TELLO • MERCEDES

THE TRINITY FOUNDER'S COLLECTION

VOLUME II

Building the Trinity Ecosystem

Midpoint Collector's Review Edition



This designed midpoint proof completes the first-half architecture through Chapter Fifteen. It consolidates the approved company distinctions, leadership roles, laboratory ownership correction, portfolio organization, operating systems, and responsibility framework before the second half is developed.

Editorial status. This is a review proof, not the final unabridged production edition. It is designed to evaluate structure, visual language, hierarchy, tables, diagrams, and the governing content of the first half. The final edition will preserve the approved manuscript at full length and incorporate final source notes, artwork, appendices, and production refinements.

Trinity & Co.

Publishing • Education • Apparel • Media • Community • Analytical Laboratory Development

Trinity Peptides LLC is a separate company founded by Gabriel. Trinity Analytical Laboratory is a division of Trinity & Co., founded and operated by Abel Ortiz.

The Standard Before the Scale

“

The purpose of this volume is not to make Trinity look larger than it is. It is to make the responsibilities clear enough that Trinity can grow without losing the truth of who built each company, who holds each authority, and what standard every future employee must protect.

ABEL ORTIZ, FOUNDER OF TRINITY & CO.

Trinity began with questions. The first volume asked what it would take to build a credible peptide-testing laboratory. The next question was larger: what kind of organization must exist around that laboratory, the product company, the publications, the apparel, the community, and the long-term mission?

This volume answers that question through structure. Gabriel receives the founder recognition and operating authority belonging to Trinity Peptides LLC. Cristina receives the co-founder and project-management authority required to turn decisions into completed work. Mercedes receives the creative authority required to make the companies recognizable without allowing design to outrun truth. Trinity & Co.'s analytical laboratory belongs to and is operated by Abel, with a development pathway toward ISO/IEC 17025 accreditation for an approved scope and with GMP-oriented professional development.

The first half is therefore a constitution of responsibility. It defines who decides, who executes, who reviews, who must be consulted, and where evidence must control preference. The second half will build upon this foundation by describing services, contracting, certification readiness, veteran support, expansion, and long-term continuity.

Abel Ortiz

FOUNDER, TRINITY & CO.

HOW TO REVIEW THIS EDITION

A Midpoint Decision Gate

This proof is intended to answer four review questions before the manuscript continues.

REVIEW AREA	DECISION TO MAKE
Structure	Does the first-half sequence move logically from mission, to leadership, to operating systems, to the final responsibility matrix?
Authority	Are the founder titles, company ownership, laboratory structure, and cross-company decision rights accurate?
Visual Standard	Does the navy, black, ivory, and gold Collector's Edition system feel appropriate for the flagship Trinity publication?
Depth	Does the balance of narrative, tables, callouts, diagrams, and operational tools create a usable constitution rather than a generic business plan?

CONTROLLING LABORATORY CORRECTION

Trinity Analytical Laboratory is a division of Trinity & Co., founded and operated by Abel Ortiz. Abel leads technical development, staffing, quality systems, equipment, methods, reporting, accreditation preparation, and GMP-oriented capability. Gabriel learns from Abel how to oversee the business use of results and supervise future product-quality personnel within Trinity Peptides LLC.

Standards note: ISO/IEC 17025 is the international standard for the competence, impartiality, and consistent operation of testing and calibration laboratories. The ASQ CPGP is an individual professional certification; it is not a laboratory accreditation or company certification. Final production citations will use official ISO and ASQ sources.

CONTENTS

First-Half Architecture

PART I — FROM AN IDEA TO AN ECOSYSTEM

- 1. The Question After the First Question
- 2. Why Trinity Must Become More Than One Business
- 3. Distinct Companies, One Mission

PART III — BUILDING THE OPERATING SYSTEM

- 10. From Ideas to Assigned Projects
- 11. The Trinity Project-Management System
- 12. Accounting and Financial Control

4. The Trinity Standard

**PART II — LEADERSHIP, AUTHORITY,
RESPONSIBILITY**

5. Gabriel: Founder of Trinity Peptides LLC

Special Portfolio Insert: Current Research Catalog

6. Abel Ortiz: Founder of Trinity & Co.

7. Cristina Tello: Co-Founder and Project Manager

8. Mercedes: Brand, Marketing and Creative Director

9. How the Leadership Team Makes Decisions

13. Inventory, Vendors, Equipment and Fulfillment

14. Publishing, Marketing, Catalogs and Social Media

15. The Trinity Responsibility Matrix

MIDPOINT DECISION GATE

First-Half Review and Approval Record

PART I

From an Idea to an Ecosystem

The first question created a business possibility. The second question required a structure capable of carrying it responsibly.

CHAPTER ONE

The Question After the First Question



Why a laboratory idea became an institutional question

The first volume began with a practical question: what would it take for an ordinary founder to understand, finance, equip, and operate a peptide-testing laboratory? The answer revealed a second question. A laboratory could not stand alone. It would require a company structure, publications, technology, supplier controls, quality systems, customer pathways, financial discipline, and leaders whose responsibilities were not interchangeable.

“The first question created a project. The second question required an ecosystem.

The Question Behind Every New Opportunity

Whenever Trinity considers a new product, book, apparel collection, laboratory method, government opportunity, or community initiative, leadership must ask what system is required around it. A project that cannot identify ownership, authority, cost, evidence, implementation, and maintenance is not ready to become a commitment.

QUESTION	OPERATING MEANING
Who owns it?	Identify the legal entity and founder authority.
Who operates it?	Assign the accountable leader and qualified personnel.
What supports it?	Define money, equipment, vendors, data, and systems.
What proves it?	Identify evidence, records, acceptance criteria, and review.
What sustains it?	Establish revenue, maintenance, training, and continuity.

FOUNDING PRINCIPLE

Trinity will not confuse a promising idea with a completed capability. Every public promise must be supported by an operating system.

CHAPTER TWO

Why Trinity Must Become More Than One Business



Different work requires different authority, systems, and
accountability

Trinity must become more than one business because the work itself belongs to different forms of authority. Product operations, publishing, apparel, analytical testing, education, contracting, and community programs do not carry identical risks, customers, assets, or qualifications.

Why One Entity Should Not Pretend to Be Everything

- **Trinity Peptides LLC** requires product, supplier, inventory, packaging, and fulfillment discipline.
- **Trinity & Co.** requires publishing, education, apparel, media, technical-development, and service capability.
- **Trinity Analytical Laboratory** requires technical competence, impartiality, controlled methods, qualified staff, and a formal quality system within Trinity & Co.
- **Government contracting** requires entity-specific registrations, representations, capability, pricing, and performance readiness.
- **Veteran and community work** requires genuine programs, privacy, delivery capacity, and measurable outcomes.

The ecosystem model allows each branch to develop the systems it genuinely needs. It also prevents one company from borrowing the title, history, certification, bank account, or technical authority of another.

“Unity is not sameness. The companies may share values while remaining accountable for different work.”

EXPANSION TEST	REQUIRED PROOF
Strategic fit	The opportunity strengthens an approved Trinity direction.
Entity fit	The correct company can lawfully and operationally perform it.
Capability	People, equipment, systems, and professional support exist or are funded.
Financial sustainability	The opportunity has a credible funding and cash-flow model.
Trust protection	The opportunity does not require exaggerated claims or hidden conflicts.

CHAPTER THREE

Distinct Companies, One Mission



Preserving legal clarity while building one recognizable ecosystem

The Trinity ecosystem is strongest when its companies cooperate without becoming structurally confused. The name may be shared. The legal entities, founders, assets, contracts, and technical authorities must remain visible.

ORGANIZATION	FOUNDER / LEADERSHIP	PRIMARY DOMAIN
Trinity Peptides LLC	Gabriel, Founder	Products, suppliers, purchasing, inventory, packaging, labeling, fulfillment, product-quality application.
Trinity & Co.	Abel Ortiz, Founder; Cristina Tello, Co-Founder	Publishing, education, apparel, media, community, technical services, government opportunities, diversified growth.
Trinity Analytical Laboratory	Founded and operated by Abel Ortiz; division of Trinity & Co.	Independent analytical testing, methods, instruments, technical reports, quality systems, accreditation development.

Intercompany Cooperation

Trinity & Co. may publish a catalog for Trinity Peptides LLC. Trinity Analytical Laboratory may test samples submitted by Trinity Peptides LLC. The companies may share selected technology, events, or creative assets. Each arrangement must identify the lead company, supporting company, payment or cost allocation, ownership of the resulting asset, confidentiality, and final authority.

IMPARTIALITY RULE

Trinity Peptides LLC may be an important laboratory client, but it cannot control the laboratory's scientific conclusions. The laboratory reports what the evidence shows.

Founder Recognition Rule

Whenever Trinity Peptides LLC is described, Gabriel must receive visible and explicit founder recognition. Abel may support the company in many executive, technical, financial, publishing, and website capacities, but he is not its founder. Whenever Trinity & Co. or its laboratory is described, Abel's founder and operator authority must remain equally clear.

CHAPTER FOUR

The Trinity Standard



The decision rule shared by every company, project,
product, and program

The Trinity Standard is the shared discipline connecting every company, division, publication, product, and program. It is not a slogan. It is a decision rule.

STANDARD	REQUIRED CONDUCT
Integrity before growth	Do not trade truth for speed, attention, or short-term revenue.
Education before hype	Explain what is known, what is uncertain, and what remains unverified.
Quality before shortcuts	Use documented processes, qualified people, reliable evidence, and corrective action.
People before transactions	Protect dignity, privacy, customer trust, employee development, and community value.
Service beyond the brand	Create practical pathways for veterans, caregivers, entrepreneurs, and future professionals.

“

A standard becomes culture only when it is visible in ordinary decisions.

The Standard in Practice

- A supplier is not approved because the price is attractive.
- A laboratory service is not marketed before the method and staff are ready.
- A certification is not claimed before it is formally earned by the correct entity or person.
- A campaign does not launch before operations can fulfill the promise.
- A founder title is not simplified in a way that changes company history.
- A veteran story is not used without permission or a real program behind it.

THE TRINITY TEST

Would the decision remain defensible if a customer, employee, accountant, laboratory assessor, government buyer, or future family member reviewed the complete record?

PART II

Leadership, Authority, Responsibility

Founder recognition, department authority, technical independence, and disciplined collaboration.

CHAPTER FIVE

Gabriel: Founder of Trinity Peptides LLC



Product operations, supplier leadership, fulfillment, and
quality-result application

Gabriel is the Founder of Trinity Peptides LLC. His title must remain visible whenever the company is described because the company’s product operations, supplier relationships, and commercial foundation originate under his leadership.

Gabriel’s Core Authority

- Product operations and commercial portfolio decisions.
- Supplier and vendor relationships, purchasing, and inventory.
- Packaging, labeling, shipping, fulfillment, and operational equipment.
- Drop-shipping evaluation and operational implementation.
- LLC, banking, merchant, and vendor research with professional support.
- Product-quality application: holds, returns, supplier escalation, and lot disposition.
- Men's apparel direction in partnership with Abel and creative execution by Mercedes.

Growing From Operator to System Leader

Gabriel's long-term responsibility is not to perform every task personally. It is to build product systems that trained personnel can follow, supervise those personnel, and preserve the operating standards of the company he founded.

LABORATORY RELATIONSHIP

Abel will teach Gabriel how to understand laboratory reports, chain of custody, identity and purity findings, supplier trends, inventory holds, and quality-control records. Gabriel will oversee how Trinity Peptides LLC uses those results; the laboratory retains authority over the scientific conclusion.

MONTHLY OPERATING VIEW	KEY QUESTION
Suppliers	Which vendors are approved, conditional, suspended, or under review?
Inventory	What is available, quarantined, held, damaged, or at risk?
Fulfillment	Are orders accurate, traceable, and shipped according to approved expectations?
Quality	What testing, complaints, or documentation issues require action?
Financial input	What purchases, freight, losses, and packaging costs affect margin and cash?

SPECIAL PORTFOLIO INSERT

Trinity Peptides LLC Current Research Catalog

Founded by Gabriel

A governance-oriented portfolio map organized by research category, product identity, evidence boundaries, supplier documentation, and public-description control.

A Catalog Is a System of Responsibility

The current portfolio spans short synthetic peptides, modified analogs, blends, proteins, hormones, vitamins, prostaglandins, biological products, and laboratory support materials. These are not one uniform product class. They require different identity records, methods, handling, storage, claims, and risk controls.

PORTFOLIO RULE	APPLICATION
Identity before description	Exact sequence, formulation, strength, product type, and supplier documentation control the public name.
Evidence before claim	Research descriptions must match the strength and type of available evidence.
Family versus SKU	Educational entries may consolidate strengths, while each commercial configuration retains its own SKU, price, and inventory record.
Laboratory independence	Testing results are reported according to technical evidence, not inventory value or launch pressure.
Founder accountability	Gabriel approves product operations; Abel supports technical review; Cristina coordinates; Mercedes controls presentation.



TRINITY PEPTIDES LLC

STRENGTH • HONOR • LONGEVITY

FOUNDED BY GABRIEL

CURRENT RESEARCH PORTFOLIO

CATALOG ENTRIES 001-017

For product questions and availability:
909-322-6375

Descriptions are plain-language research summaries.
For Research Use Only. No dosing or treatment guidance.

#	Catalog No.	Product Name	Short Research Focus	Additional Information
1	10AM	5-Amino-1MQ 10 mg	Metabolic / Weight Research	10 mg x 10 vials. NNMT-related metabolic pathway research
2	50AM	5-Amino-1MQ 50 mg	Metabolic / Weight Research	50 mg x 10 vials. NNMT-related metabolic pathway research
3	5AM	5-Amino-1MQ 5 mg	Metabolic / Weight Research	5 mg x 10 vials. NNMT-related metabolic pathway research
4	AE1	ACE-031 1 mg	Growth / Endocrine	1 mg x 10 vials. ActRIIB and myostatin-pathway research
5	AA10	Acetic Acid Water (10 mL, 1 Vial)	Laboratory Diluent	10 mL / 1 vial. Acidified support material; verify exact concentration
6	AD5	Adamax 5 mg	Cognitive / Neurological	5 mg x 10 vials. Neuro-focused research item; identity documentation required
7	AP2	Adipotide 2 mg	Metabolic / Weight Research	2 mg x 10 vials. Adipose-vascular targeting research models
8	AP5	Adipotide 5 mg	Metabolic / Weight Research	5 mg x 10 vials. Adipose-vascular targeting research models
9	AU100	AHK-CU 100 mg	Healing / Tissue Repair	100 mg x 10 vials. Copper-binding peptide for skin and tissue research
10	AR100	AICAR 100 mg	Metabolic / Weight Research	100 mg x 10 vials. AMPK and cellular energy-metabolism research
11	AR50	AICAR 50 mg	Metabolic / Weight Research	50 mg x 10 vials. AMPK and cellular energy-metabolism research
12	PRO20	Alprostadi1 20 mcg	Neuromuscular / Vascular	20 mcg x 5 vials. Prostaglandin-related vascular signaling research
13	10AD	AOD-9604 10 mg	Metabolic / Weight Research	10 mg x 10 vials. HGH-fragment-derived metabolic research
14	2AD	AOD-9604 2 mg	Metabolic / Weight Research	2 mg x 10 vials. HGH-fragment-derived metabolic research
15	5AD	AOD-9604 5 mg	Metabolic / Weight Research	5 mg x 10 vials. HGH-fragment-derived metabolic research
16	RA10	ARA-290 10 mg	General Research	10 mg x 10 vials. Tissue-protective receptor and neuropathy research
17	B12	B12 10vials	Vitamin / Hematology	10 vials. Vitamin-cofactor and hematology research



TRINITY PEPTIDES LLC

STRENGTH • HONOR • LONGEVITY

FOUNDED BY GABRIEL

CURRENT RESEARCH PORTFOLIO

CATALOG ENTRIES 018-034

For product questions and availability:

909-322-6375

Descriptions are plain-language research summaries.

For Research Use Only. No dosing or treatment guidance.

#	Catalog No.	Product Name	Short Research Focus	Additional Information
18	BA10	Bacteriostatic Water (10 mL, 1 Vial)	Laboratory Diluent	10 mL / 1 vial. Preservative-containing diluent; verify composition
19	BA03	Bacteriostatic Water (3 mL, 1 Vial)	Laboratory Diluent	3 mL / 1 vial. Preservative-containing diluent; verify composition
20	BA05	Bacteriostatic Water (5 mL, 1 Vial)	Laboratory Diluent	5 mL / 1 vial. Preservative-containing diluent; verify composition
21	XT100	Botulinum Toxin Type A 100 IU	Neuromuscular / Vascular	100 IU / 1 vial. Neuromuscular signaling research; enhanced controls
22	BB20	Wolverine Blend (BPC-157 10 mg + TB-500 10 mg)	Healing / Tissue Repair	20 mg x 10 vials. BPC-157 and TB-500 tissue-repair research blend
23	BC10	BPC-157 10 mg	Healing / Tissue Repair	10 mg x 10 vials. Tissue-response and repair-pathway research
24	BBG70	GLOW Blend (BPC-157 10 mg + GHK-Cu 50 mg + TB-500 10 mg)	Healing / Tissue Repair	70 mg x 10 vials. BPC-157, GHK-Cu and TB-500 remodeling blend
25	KL80	KLOW Blend (BPC-157 10 mg + GHK-Cu 50 mg + TB-500 10 mg + KPV 10 mg)	Healing / Tissue Repair	80 mg x 10 vials. Tissue-remodeling blend with KPV signaling component
26	BC20	BPC-157 20 mg	Healing / Tissue Repair	20 mg x 10 vials. Tissue-response and repair-pathway research
27	BC2	BPC-157 2 mg	Healing / Tissue Repair	2 mg x 10 vials. Tissue-response and repair-pathway research
28	BC5	BPC-157 5 mg	Healing / Tissue Repair	5 mg x 10 vials. Tissue-response and repair-pathway research
29	BB4	Wolverine Blend (BPC-157 2 mg + TB-500 2 mg)	Healing / Tissue Repair	4 mg x 10 vials. BPC-157 and TB-500 tissue-repair research blend
30	BB10	Wolverine Blend (BPC-157 5 mg + TB-500 5 mg)	Healing / Tissue Repair	10 mg x 10 vials. BPC-157 and TB-500 tissue-repair research blend
31	BR20	Bronchogen 20 mg	Immune / Bioregulator	20 mg x 10 vials. Pulmonary peptide-bioregulator research
32	CGL10	Cagrilintide 10 mg	Metabolic / Weight Research	10 mg x 10 vials. Amylin-analog appetite and metabolic research
33	CGL20	Cagrilintide 20 mg	Metabolic / Weight Research	20 mg x 10 vials. Amylin-analog appetite and metabolic research
34	CGL5	Cagrilintide 5 mg	Metabolic / Weight Research	5 mg x 10 vials. Amylin-analog appetite and metabolic research



TRINITY PEPTIDES LLC

STRENGTH • HONOR • LONGEVITY

FOUNDED BY GABRIEL

CURRENT RESEARCH PORTFOLIO

CATALOG ENTRIES 035-051

For product questions and availability:

909-322-6375

Descriptions are plain-language research summaries.

For Research Use Only. No dosing or treatment guidance.

#	Catalog No.	Product Name	Short Research Focus	Additional Information
35	CS10	CagriSema Blend (Cagrilintide 5 mg + Semaglutide 5 mg)	Metabolic / Weight Research	10 mg x 10 vials. Amylin-analog appetite and metabolic research
36	CA20	Cardiogen 20 mg	Immune / Bioregulator	20 mg x 10 vials. Cardiac-tissue peptide-bioregulator research
37	LAX20	Cartalax 20 mg	Healing / Tissue Repair	20 mg x 10 vials. Cartilage and connective-tissue bioregulator research
38	CBL60	Cerebrolysin 60 mg	Cognitive / Neurological	60 mg x 6 vials. Neurotrophic peptide-mixture research
39	LCAR	L-Carnitine 10 mL (600 mg/mL)	Cognitive / Neurological	10 mL/10 vials. Fatty-acid transport and cellular-energy research
40	CH20	Chonluten 20 mg	Immune / Bioregulator	20 mg x 10 vials. Pulmonary-tissue peptide-bioregulator research
41	CND10	CJC-1295 No DAC 10 mg	Growth / Endocrine	10 mg x 10 vials. Shorter-duration GHRH-receptor analog research
42	CND2	CJC-1295 No DAC 2 mg	Growth / Endocrine	2 mg x 10 vials. Shorter-duration GHRH-receptor analog research
43	CND5	CJC-1295 No DAC 5 mg	Growth / Endocrine	5 mg x 10 vials. Shorter-duration GHRH-receptor analog research
44	CD10	CJC-1295 With DAC 10 mg	Growth / Endocrine	10 mg x 10 vials. Extended-duration GHRH-analog research
45	CD2	CJC-1295 With DAC 2 mg	Growth / Endocrine	2 mg x 10 vials. Extended-duration GHRH-analog research
46	CD5	CJC-1295 With DAC 5 mg	Growth / Endocrine	5 mg x 10 vials. Extended-duration GHRH-analog research
47	CP20	CJC-1295/Ipamorelin Blend (CJC-1295 No DAC 10 mg + Ipamorelin 10 mg)	Growth / Endocrine	20 mg x 10 vials. Combined GHRH and ghrelin-receptor research
48	CP10	CJC-1295/Ipamorelin Blend (CJC-1295 No DAC 5 mg + Ipamorelin 5 mg)	Growth / Endocrine	10 mg x 10 vials. Combined GHRH and ghrelin-receptor research
49	COR20	Cortagen 20 mg	Cognitive / Neurological	20 mg x 10 vials. Brain peptide-bioregulator research
50	CRY20	Crystagen 20 mg	Immune / Bioregulator	20 mg x 10 vials. Thymic and immune-bioregulator research
51	DR5	Dermorphin 5 mg	Cognitive / Neurological	5 mg x 10 vials. Opioid-receptor research peptide



TRINITY PEPTIDES LLC

STRENGTH • HONOR • LONGEVITY

FOUNDED BY GABRIEL

CURRENT RESEARCH PORTFOLIO

CATALOG ENTRIES 052-068

For product questions and availability:

909-322-6375

Descriptions are plain-language research summaries.

For Research Use Only. No dosing or treatment guidance.

#	Catalog No.	Product Name	Short Research Focus	Additional Information
52	DS10	DSIP 10 mg	Cognitive / Neurological	10 mg x 10 vials. Sleep, stress-response and neuropeptide research
53	DS15	DSIP 15 mg	Cognitive / Neurological	15 mg x 10 vials. Sleep, stress-response and neuropeptide research
54	DS2	DSIP 2 mg	Cognitive / Neurological	2 mg x 10 vials. Sleep, stress-response and neuropeptide research
55	DS5	DSIP 5 mg	Cognitive / Neurological	5 mg x 10 vials. Sleep, stress-response and neuropeptide research
56	ET10	Epithalon 10 mg	General Research	10 mg x 10 vials. Cellular-aging, telomere and bioregulator research
57	ET40	Epithalon 40 mg	General Research	40 mg x 10 vials. Cellular-aging, telomere and bioregulator research
58	ET50	Epithalon 50 mg	General Research	50 mg x 10 vials. Cellular-aging, telomere and bioregulator research
59	E3K	Erythropoietin (EPO) 3,000 IU	Vitamin / Hematology	3000 IU x 5 vials. Erythropoiesis biology; high-consequence biologic
60	F410	FOXO4-DRI 10 mg	General Research	10 mg x 10 vials. FOXO4-p53 and cellular-senescence research
61	GH50	GHK (Basic) 50 mg	General Research	50 mg x 10 vials. Copper-free GHK for skin and tissue research
62	CU100	GHK-Cu 100 mg	Healing / Tissue Repair	100 mg x 10 vials. Copper peptide for skin and tissue-remodeling research
63	CU50	GHK-Cu 50 mg	Healing / Tissue Repair	50 mg x 10 vials. Copper peptide for skin and tissue-remodeling research
64	G210	GHRP-2 Acetate 10 mg	Growth / Endocrine	10 mg x 10 vials. Ghrelin-receptor and GH-secretagogue research
65	G25	GHRP-2 Acetate 5 mg	Growth / Endocrine	5 mg x 10 vials. Ghrelin-receptor and GH-secretagogue research
66	G610	GHRP-6 Acetate 10 mg	Growth / Endocrine	10 mg x 10 vials. Ghrelin-receptor and GH-secretagogue research
67	G65	GHRP-6 Acetate 5 mg	Growth / Endocrine	5 mg x 10 vials. Ghrelin-receptor and GH-secretagogue research
68	GT1200	Glutathione 1200 mg	Mitochondrial / Antioxidant	1200 mg x 10 vials. Antioxidant, redox and cellular-defense research



TRINITY PEPTIDES LLC

STRENGTH • HONOR • LONGEVITY

FOUNDED BY GABRIEL

CURRENT RESEARCH PORTFOLIO

CATALOG ENTRIES 069-085

For product questions and availability:
909-322-6375

Descriptions are plain-language research summaries.
For Research Use Only. No dosing or treatment guidance.

#	Catalog No.	Product Name	Short Research Focus	Additional Information
69	G1200	Glutathione 1200 mg	Mitochondrial / Antioxidant	1200 mg x 10 vials. Antioxidant, redox and cellular-defense research
70	GTT	Glutathione 1500 mg	Mitochondrial / Antioxidant	1500 mg x 10 vials. Antioxidant, redox and cellular-defense research
71	GT1500	Glutathione 1500 mg	Mitochondrial / Antioxidant	1500 mg x 10 vials. Antioxidant, redox and cellular-defense research
72	G600	Glutathione 600 mg	Mitochondrial / Antioxidant	600 mg x 10 vials. Antioxidant, redox and cellular-defense research
73	GND2	Gonadorelin Acetate 2 mg	Hormonal / Reproductive	2 mg x 10 vials. GnRH and reproductive-endocrine signaling research
74	G10K	HCG 10000 IU	Hormonal / Reproductive	10000 IU x 10 vials. Gonadotropin and reproductive-endocrine research
75	G2K	HCG 2000 IU	Hormonal / Reproductive	2000 IU x 10 vials. Gonadotropin and reproductive-endocrine research
76	G5K	HCG 5000 IU	Hormonal / Reproductive	5000 IU x 10 vials. Gonadotropin and reproductive-endocrine research
77	HX2	Hexarelin Acetate 2 mg	Growth / Endocrine	2 mg x 10 vials. Ghrelin-receptor and GH-secretagogue research
78	HX5	Hexarelin Acetate 5 mg	Growth / Endocrine	5 mg x 10 vials. Ghrelin-receptor and GH-secretagogue research
79	H10	HGH 191AA (Somatropin) 10 IU	Growth / Endocrine	10 IU x 10 vials. Growth-hormone protein; identity and potency controls
80	H12	HGH 191AA (Somatropin) 12 IU	Growth / Endocrine	12 IU x 10 vials. Growth-hormone protein; identity and potency controls
81	H15	HGH 191AA (Somatropin) 15 IU	Growth / Endocrine	15 IU x 10 vials. Growth-hormone protein; identity and potency controls
82	H24	HGH 191AA (Somatropin) 24 IU	Growth / Endocrine	24 IU x 10 vials. Growth-hormone protein; identity and potency controls
83	H36	HGH 191AA (Somatropin) 36 IU	Growth / Endocrine	36 IU x 10 vials. Growth-hormone protein; identity and potency controls
84	H06	HGH 191AA (Somatropin) 6 IU	Growth / Endocrine	6 IU x 10 vials. Growth-hormone protein; identity and potency controls
85	FR10	HGH Fragment 176-191 10 mg	Growth / Endocrine	10 mg x 10 vials. Growth-hormone-fragment metabolic research



TRINITY PEPTIDES LLC

STRENGTH • HONOR • LONGEVITY

FOUNDED BY GABRIEL

CURRENT RESEARCH PORTFOLIO

CATALOG ENTRIES 086-102

For product questions and availability:
909-322-6375

Descriptions are plain-language research summaries.
For Research Use Only. No dosing or treatment guidance.

#	Catalog No.	Product Name	Short Research Focus	Additional Information
86	FR2	HGH Fragment 176-191 2 mg	Growth / Endocrine	2 mg x 10 vials. Growth-hormone-fragment metabolic research
87	FR5	HGH Fragment 176-191 5 mg	Growth / Endocrine	5 mg x 10 vials. Growth-hormone-fragment metabolic research
88	G75	HMG 75 IU	Hormonal / Reproductive	75 IU x 10 vials. Gonadotropin and fertility-pathway research
89	HU10	Humanin 10 mg	Cognitive / Neurological	10 mg x 10 vials. Mitochondrial-derived peptide and neural research
90	HA5	Hyaluronic Acid 5 mg	Healing / Tissue Repair	5 mg x 1 vial. Extracellular-matrix and tissue-hydration research
91	IG01	IGF-1 LR3 0.1 mg	Growth / Endocrine	0.1 mg x 10 vials. Long-acting IGF-pathway research analog
92	IG1	IGF-1 LR3 1 mg	Growth / Endocrine	1 mg x 10 vials. Long-acting IGF-pathway research analog
93	IGF-DES	IGF-1 DES	Growth / Endocrine	10 vials. Short IGF-1 analog and growth-signaling research
94	IP10	Ipamorelin 10 mg	Growth / Endocrine	10 mg x 10 vials. Selective ghrelin-receptor secretagogue research
95	IP2	Ipamorelin 2 mg	Growth / Endocrine	2 mg x 10 vials. Selective ghrelin-receptor secretagogue research
96	IP5	Ipamorelin 5 mg	Growth / Endocrine	5 mg x 10 vials. Selective ghrelin-receptor secretagogue research
97	KS10	Kisspeptin-10 10 mg	Hormonal / Reproductive	10 mg x 10 vials. Kisspeptin/GnRH reproductive-signaling research
98	KS5	Kisspeptin-10 5 mg	Hormonal / Reproductive	5 mg x 10 vials. Kisspeptin/GnRH reproductive-signaling research
99	KP10	KPV 10 mg	Healing / Tissue Repair	10 mg x 10 vials. Inflammatory-signaling and tissue-response research
100	LP-C	Lipo-C 10 mL	Healing / Tissue Repair	10 mL+10 vials. Lipotropic mixture; exact composition verification required
101	LP-CB12	Lipo-C Without B12 10 mL	Metabolic / Weight Research	10 mg x 10 vials. Vitamin-cofactor and hematology research
102	LL30	Liraglutide 30 mg	Metabolic / Weight Research	30 mg x 10 vials. GLP-1 receptor metabolic research



TRINITY PEPTIDES LLC

STRENGTH • HONOR • LONGEVITY

FOUNDED BY GABRIEL

CURRENT RESEARCH PORTFOLIO

CATALOG ENTRIES 103-119

For product questions and availability:

909-322-6375

Descriptions are plain-language research summaries.

For Research Use Only. No dosing or treatment guidance.

#	Catalog No.	Product Name	Short Research Focus	Additional Information
103	LL5	Liraglutide 5 mg	Metabolic / Weight Research	5 mg x 10 vials. GLP-1 receptor metabolic research
104	LI20	Livagen 20 mg	Immune / Bioregulator	20 mg x 10 vials. Liver peptide-bioregulator research
105	375	LL-37 5 mg	Healing / Tissue Repair	5 mg x 10 vials. Innate-immune and antimicrobial peptide research
106	MA10	Matrixyl 10 mg	Healing / Tissue Repair	10 mg x 10 vials. Cosmetic peptide and collagen-signaling research
107	MDT10	Mazdutide 10 mg	Metabolic / Weight Research	10 mg x 10 vials. Dual-receptor metabolic pathway research
108	MDT5	Mazdutide 5 mg	Metabolic / Weight Research	5 mg x 10 vials. Dual-receptor metabolic pathway research
109	MT10	Melanotan I 10 mg	Mitochondrial / Antioxidant	10 mg x 10 vials. Melanocortin and pigmentation-pathway research
110	FM2	MGF 2 mg	Growth / Endocrine	2 mg x 10 vials. IGF-related mechano-growth-factor research
111	MS10	MOTS-c 10 mg	Mitochondrial / Antioxidant	10 mg x 10 vials. Mitochondrial-derived peptide and metabolic research
112	MS40	MOTS-c 40 mg	Mitochondrial / Antioxidant	40 mg x 10 vials. Mitochondrial-derived peptide and metabolic research
113	MT1	Melanotan I 10 mg	Melanocortin / Receptor	10 mg x 10 vials. Melanocortin and pigmentation-pathway research
114	ML10	Melanotan II 10 mg	Melanocortin / Receptor	10 mg x 10 vials. Melanocortin and pigmentation-pathway research
115	ML5	Melanotan II 5 mg	Melanocortin / Receptor	5 mg x 10 vials. Melanocortin and pigmentation-pathway research
116	NET5	N-Acetyl Epitalon Amide 5 mg	General Research	5 mg x 10 vials. Modified Epitalon analog; direct evidence required
117	NSK30	N-Acetyl Selank Amide 30 mg	Cognitive / Neurological	30 mg x 10 vials. Modified Selank analog; formulation-specific evidence
118	NXA30	N-Acetyl Semax Amide 30 mg	Cognitive / Neurological	30 mg x 10 vials. Modified Semax analog; formulation-specific evidence
119	NJ1000	NAD + 1000 mg	Mitochondrial / Antioxidant	1000 mg x 10 vials. Redox cofactor and cellular-energy research



TRINITY PEPTIDES LLC

STRENGTH • HONOR • LONGEVITY

FOUNDED BY GABRIEL

CURRENT RESEARCH PORTFOLIO

CATALOG ENTRIES 120-136

For product questions and availability:

909-322-6375

Descriptions are plain-language research summaries.

For Research Use Only. No dosing or treatment guidance.

#	Catalog No.	Product Name	Short Research Focus	Additional Information
120	NJ3100	NAD + 100 mg	Mitochondrial / Antioxidant	100 mg x 10 vials. Redox cofactor and cellular-energy research
121	NJ250	NAD + 250 mg	Mitochondrial / Antioxidant	250 mg x 10 vials. Redox cofactor and cellular-energy research
122	NJ500	NAD + 500 mg	Mitochondrial / Antioxidant	500 mg x 10 vials. Redox cofactor and cellular-energy research
123	OV20	Ovagen 20 mg	Immune / Bioregulator	20 mg x 10 vials. Ovarian-tissue peptide-bioregulator research
124	OT10	Oxytocin Acetate 10 mg	Hormonal / Reproductive	10 mg x 10 vials. Oxytocin-receptor and reproductive signaling research
125	OT2	Oxytocin Acetate 2 mg	Hormonal / Reproductive	2 mg x 10 vials. Oxytocin-receptor and reproductive signaling research
126	OT5	Oxytocin Acetate 5 mg	Hormonal / Reproductive	5 mg x 10 vials. Oxytocin-receptor and reproductive signaling research
127	P210	P21 10 mg	Cognitive / Neurological	10 mg x 10 vials. Preclinical neurogenesis and cognitive-pathway research
128	PP10	P21 50 mg	Cognitive / Neurological	50 mg x 10 vials. Preclinical neurogenesis and cognitive-pathway research
129	PA20	Pancragen 20 mg	Immune / Bioregulator	20 mg x 10 vials. Pancreatic-tissue peptide-bioregulator research
130	PE10	PE-22-28 10 mg	Cognitive / Neurological	10 mg x 10 vials. Neurotrophic and cognitive-signaling research
131	FMP2	PEG-MGF 2 mg	Growth / Endocrine	2 mg x 10 vials. IGF-related mechano-growth-factor research
132	PIN10	Pinealon 10 mg	Cognitive / Neurological	10 mg x 10 vials. Short-peptide brain bioregulator research
133	PIN20	Pinealon 20 mg	Cognitive / Neurological	20 mg x 10 vials. Short-peptide brain bioregulator research
134	PIN5	Pinealon 5 mg	Cognitive / Neurological	5 mg x 10 vials. Short-peptide brain bioregulator research
135	PN10	PNC-27 10 mg	General Research	10 mg x 10 vials. Experimental oncology and membrane-targeting research
136	PN5	PNC-27 5 mg	General Research	5 mg x 10 vials. Experimental oncology and membrane-targeting research



TRINITY PEPTIDES LLC

STRENGTH • HONOR • LONGEVITY

FOUNDED BY GABRIEL

CURRENT RESEARCH PORTFOLIO

CATALOG ENTRIES 137-152

For product questions and availability:

909-322-6375

Descriptions are plain-language research summaries.

For Research Use Only. No dosing or treatment guidance.

#	Catalog No.	Product Name	Short Research Focus	Additional Information
137	MAX20	Prostamax 20 mg	Immune / Bioregulator	20 mg x 10 vials. Prostate-tissue peptide-bioregulator research
138	P41	PT-141 10 mg	Melanocortin / Receptor	10 mg x 10 vials. Melanocortin-receptor signaling research
139	PTD5	PTD-DBM 5 mg	Healing / Tissue Repair	5 mg x 10 vials. Bone, cartilage and Wnt-pathway research
140	RT10	Retatrutide 10 mg	Metabolic / Weight Research	10 mg x 10 vials. Triple-receptor metabolic pathway research
141	RT15	Retatrutide 15 mg	Metabolic / Weight Research	15 mg x 10 vials. Triple-receptor metabolic pathway research
142	RT20	Retatrutide 20 mg	Metabolic / Weight Research	20 mg x 10 vials. Triple-receptor metabolic pathway research
143	RT30	Retatrutide 30 mg	Metabolic / Weight Research	30 mg x 10 vials. Triple-receptor metabolic pathway research
144	RT40	Retatrutide 40 mg	Metabolic / Weight Research	40 mg x 10 vials. Triple-receptor metabolic pathway research
145	RT50	Retatrutide 50 mg	Metabolic / Weight Research	50 mg x 10 vials. Triple-receptor metabolic pathway research
146	RT5	Retatrutide 5 mg	Metabolic / Weight Research	5 mg x 10 vials. Triple-receptor metabolic pathway research
147	RC10	RetaCagri Blend (Retatrutide 5 mg + Cagrilintide 5 mg)	Metabolic / Weight Research	10 mg x 10 vials. Amylin-analog appetite and metabolic research
148	RT60	Retatrutide 60 mg	Metabolic / Weight Research	60 mg x 10 vials. Triple-receptor metabolic pathway research
149	SK10	Selank 10 mg	Cognitive / Neurological	10 mg x 10 vials. Stress-response and neuropeptide signaling research
150	SK30	Selank 30 mg	Cognitive / Neurological	30 mg x 10 vials. Stress-response and neuropeptide signaling research
151	SK5	Selank 5 mg	Cognitive / Neurological	5 mg x 10 vials. Stress-response and neuropeptide signaling research
152	SM10	Semaglutide 10 mg	Metabolic / Weight Research	10 mg x 10 vials. GLP-1 receptor metabolic research



TRINITY PEPTIDES LLC

STRENGTH • HONOR • LONGEVITY

FOUNDED BY GABRIEL

CURRENT RESEARCH PORTFOLIO

CATALOG ENTRIES 153-168

For product questions and availability:
909-322-6375

Descriptions are plain-language research summaries.
For Research Use Only. No dosing or treatment guidance.

#	Catalog No.	Product Name	Short Research Focus	Additional Information
153	SM15	Semaglutide 15 mg	Metabolic / Weight Research	15 mg x 10 vials. GLP-1 receptor metabolic research
154	SM20	Semaglutide 20 mg	Metabolic / Weight Research	20 mg x 10 vials. GLP-1 receptor metabolic research
155	SM2	Semaglutide 2 mg	Metabolic / Weight Research	2 mg x 10 vials. GLP-1 receptor metabolic research
156	SM30	Semaglutide 30 mg	Metabolic / Weight Research	30 mg x 10 vials. GLP-1 receptor metabolic research
157	SM5	Semaglutide 5 mg	Metabolic / Weight Research	5 mg x 10 vials. GLP-1 receptor metabolic research
158	XA10	Semax 10 mg	Cognitive / Neurological	10 mg x 10 vials. Neurotrophic and cognitive-signaling research
159	XS20	Semax/Selank Blend (Semax 10 mg + Selank 10 mg)	Cognitive / Neurological	20 mg x 10 vials. Stress-response and neuropeptide signaling research
160	XA30	Semax 30 mg	Cognitive / Neurological	30 mg x 10 vials. Neurotrophic and cognitive-signaling research
161	XA5	Semax 5 mg	Cognitive / Neurological	5 mg x 10 vials. Neurotrophic and cognitive-signaling research
162	SMO10	Sermorelin Acetate 10 mg	Growth / Endocrine	10 mg x 10 vials. GHRH analog and growth-hormone signaling research
163	SMO15	Sermorelin Acetate 15 mg	Growth / Endocrine	15 mg x 10 vials. GHRH analog and growth-hormone signaling research
164	SMO2	Sermorelin Acetate 2 mg	Growth / Endocrine	2 mg x 10 vials. GHRH analog and growth-hormone signaling research
165	SMO5	Sermorelin Acetate 5 mg	Growth / Endocrine	5 mg x 10 vials. GHRH analog and growth-hormone signaling research
166	332	SLU-PP-332 5 mg	Metabolic / Weight Research	5 mg x 10 vials. ERR-pathway and exercise-mimetic research
167	NP810	SNAP-8 10 mg	Neuromuscular / Vascular	10 mg x 10 vials. Acetyl-octapeptide neuromuscular/cosmetic research
168	2S10	SS-31 10 mg	Mitochondrial / Antioxidant	10 mg x 10 vials. Mitochondrial membrane and cardiolipin research



TRINITY PEPTIDES LLC

STRENGTH • HONOR • LONGEVITY

FOUNDED BY GABRIEL

CURRENT RESEARCH PORTFOLIO

CATALOG ENTRIES 169-184

For product questions and availability:

909-322-6375

Descriptions are plain-language research summaries.

For Research Use Only. No dosing or treatment guidance.

#	Catalog No.	Product Name	Short Research Focus	Additional Information
169	2S50	SS-31 50 mg	Mitochondrial / Antioxidant	50 mg x 10 vials. Mitochondrial membrane and cardiolipin research
170	SUR10	Survodutide 10 mg	Metabolic / Weight Research	10 mg x 10 vials. Dual glucagon/GLP-1 pathway research
171	B10F	TB-500 Fragment 17-23 10 mg	Healing / Tissue Repair	10 mg x 10 vials. Defined TB-500 fragment; distinguish full Tbeta4
172	BT10	TB-500 (Thymosin Beta-4) 10 mg	Healing / Tissue Repair	10 mg x 10 vials. Thymosin beta-4 tissue and actin-pathway research
173	BT20	TB-500 (Thymosin Beta-4) 20 mg	Healing / Tissue Repair	20 mg x 10 vials. Thymosin beta-4 tissue and actin-pathway research
174	BT2	TB-500 (Thymosin Beta-4) 2 mg	Healing / Tissue Repair	2 mg x 10 vials. Thymosin beta-4 tissue and actin-pathway research
175	BT5	TB-500 (Thymosin Beta-4) 5 mg	Healing / Tissue Repair	5 mg x 10 vials. Thymosin beta-4 tissue and actin-pathway research
176	TER10	Teriparatide 10 mg	Hormonal / Reproductive	10 mg x 10 vials. PTH-receptor and bone-metabolism research
177	TSM10	Tesamorelin 10 mg	Growth / Endocrine	10 mg x 10 vials. GHRH-analog endocrine and metabolic research
178	TI18	Tesamorelin/Ipamorelin Blend (Tesamorelin 12 mg + Ipamorelin 6 mg)	Growth / Endocrine	18 mg x 10 vials. Selective ghrelin-receptor secretagogue research
179	TSM20	Tesamorelin 20 mg	Growth / Endocrine	20 mg x 10 vials. GHRH-analog endocrine and metabolic research
180	TSM2	Tesamorelin 2 mg	Growth / Endocrine	2 mg x 10 vials. GHRH-analog endocrine and metabolic research
181	TSM5	Tesamorelin 5 mg	Growth / Endocrine	5 mg x 10 vials. GHRH-analog endocrine and metabolic research
182	TG20	Testagen 20 mg	Hormonal / Reproductive	20 mg x 10 vials. Testicular and reproductive-bioregulator research
183	TY10	Thymalin 10 mg	Immune / Bioregulator	10 mg x 10 vials. Thymic peptide-mixture and bioregulator research
184	TA10	Thymosin Alpha-1 10 mg	Immune / Bioregulator	10 mg x 10 vials. Immune-signaling peptide research



TRINITY PEPTIDES LLC

STRENGTH • HONOR • LONGEVITY

FOUNDED BY GABRIEL

CURRENT RESEARCH PORTFOLIO

CATALOG ENTRIES 185-200

For product questions and availability:
909-322-6375

Descriptions are plain-language research summaries.
For Research Use Only. No dosing or treatment guidance.

#	Catalog No.	Product Name	Short Research Focus	Additional Information
185	TA2	Thymosin Alpha-1 2 mg	Immune / Bioregulator	2 mg x 10 vials. Immune-signaling peptide research
186	TA5	Thymosin Alpha-1 5 mg	Immune / Bioregulator	5 mg x 10 vials. Immune-signaling peptide research
187	TR100	Tirzepatide 100 mg	Metabolic / Weight Research	100 mg x 10 vials. Dual GIP/GLP-1 receptor metabolic research
188	TR10	Tirzepatide 10 mg	Metabolic / Weight Research	10 mg x 10 vials. Dual GIP/GLP-1 receptor metabolic research
189	TR120	Tirzepatide 120 mg	Metabolic / Weight Research	120 mg x 10 vials. Dual GIP/GLP-1 receptor metabolic research
190	TR15	Tirzepatide 15 mg	Metabolic / Weight Research	15 mg x 10 vials. Dual GIP/GLP-1 receptor metabolic research
191	TR20	Tirzepatide 20 mg	Metabolic / Weight Research	20 mg x 10 vials. Dual GIP/GLP-1 receptor metabolic research
192	TR30	Tirzepatide 30 mg	Metabolic / Weight Research	30 mg x 10 vials. Dual GIP/GLP-1 receptor metabolic research
193	TR40	Tirzepatide 40 mg	Metabolic / Weight Research	40 mg x 10 vials. Dual GIP/GLP-1 receptor metabolic research
194	TR50	Tirzepatide 50 mg	Metabolic / Weight Research	50 mg x 10 vials. Dual GIP/GLP-1 receptor metabolic research
195	TR5	Tirzepatide 5 mg	Metabolic / Weight Research	5 mg x 10 vials. Dual GIP/GLP-1 receptor metabolic research
196	TR60	Tirzepatide 60 mg	Metabolic / Weight Research	60 mg x 10 vials. Dual GIP/GLP-1 receptor metabolic research
197	VE20	Vesugen 20 mg	Immune / Bioregulator	20 mg x 10 vials. Vascular and endothelial bioregulator research
198	VI20	Vilon 20 mg	Immune / Bioregulator	20 mg x 10 vials. Lys-Glu thymic and immune-bioregulator research
199	VP10	VIP 10 mg	General Research	10 mg x 10 vials. Neuroimmune, vascular and smooth-muscle signaling research
200	VP5	VIP 5 mg	General Research	5 mg x 10 vials. Neuroimmune, vascular and smooth-muscle signaling research

The Product Verification Register

Every product family should connect to a controlled record showing its exact identity, supplier, manufacturer when known, configuration, sequence or formula when relevant, Certificate of Analysis, independent testing status, storage, category, evidence level, label version, availability, and approval.

STATUS	MEANING
Active	Documentation and operational controls support the approved listing.
Conditional	The product remains available only under defined testing or documentation requirements.
Technical-description hold	The exact identity or formulation is insufficiently documented for broader public wording.
Inventory hold	The lot is unavailable while a quality, label, storage, or documentation concern is investigated.
Discontinued	The product is removed from active commercial operations and archived.

“

The Trinity catalog will not merely show what the company carries. It will demonstrate how responsibly the company understands what it carries.

CHAPTER SIX

Abel Ortiz: Founder of Trinity & Co.



Publishing, strategy, financial systems, technology,
contracting, and laboratory leadership

Abel Ortiz is the Founder of Trinity & Co. He leads the company's publishing, education, strategic development, technical systems, financial planning, government-contracting readiness, diversified opportunities, and analytical laboratory division.

LEADERSHIP DOMAIN	ABEL'S RESPONSIBILITY
Publishing	Editorial architecture, source control, production standard, intellectual property, distribution strategy.
Financial systems	Cost models, pricing analysis, cash forecasting, project budgets, accounting coordination.
Technology	Websites, data architecture, access control, backups, cybersecurity planning, platform integration.
Government opportunities	Capability development, registrations, entity-specific representations, pricing, proposal strategy.
Analytical laboratory	Ownership, operations, staffing, instruments, methods, quality systems, reporting, accreditation development.

LABORATORY AUTHORITY

Trinity Analytical Laboratory is a division of Trinity & Co. Abel leads the development toward ISO/IEC 17025 accreditation for a defined scope and pursues GMP/cGMP training and eligible professional credentials such as the ASQ CPGP. The CPGP is an individual certification, not a company or laboratory accreditation.

Strategic Sponsor, Not Universal Task Owner

Abel defines why major Trinity & Co. projects exist, what financial and strategic boundaries apply, and when a project should continue, pause, or stop. Cristina manages the organized path to completion. Mercedes leads creative execution. Gabriel retains founder authority over Trinity Peptides LLC product operations.

“ Abel's role is to connect ideas to systems, systems to evidence, and evidence to disciplined decisions.

CHAPTER SEVEN

Cristina Tello: Co-Founder and Project Manager



Turning leadership decisions into visible execution

Cristina Tello is Co-Founder of Trinity & Co. and Project Manager for both Trinity & Co. and Trinity Peptides LLC. Her role is to convert approved decisions into visible plans, assigned responsibilities, reliable deadlines, documented changes, and completed deliverables.

CRISTINA LEADS	CRISTINA DOES NOT AUTOMATICALLY APPROVE
Project plans, action registers, deadlines, meetings, status reports, vendor follow-up.	Founder strategy, major budgets, product release, technical conclusions, legal representations.
Customer-experience workflows, social-account coordination, community program implementation.	Individualized scientific or medical guidance, laboratory report release, accreditation claims.
Women's apparel development with Mercedes, sample tracking, sizing, launch readiness.	Unapproved production commitments or changes to founder titles.

The Project Cycle

STAGE	CONTROL
Request	Capture the idea without treating it as approved.
Evaluation	Identify company, purpose, capability, cost, risk, and authority.
Approval	Record scope, sponsor, owner, budget, and decision gates.
Planning	Break the work into deliverables, tasks, milestones, and dependencies.
Execution	Track progress, changes, risks, and communication.
Verification	Confirm that deliverables meet the approved requirements.
Closure	Archive records and transfer continuing work into operations.

“

Cristina does not need to perform every task. She must ensure that every approved task has an owner, a deadline, and a visible status.

CHAPTER EIGHT

Mercedes: Brand, Marketing and Creative Director



Building the visual and audience-facing system of the
Trinity ecosystem

Mercedes serves as Brand, Marketing and Creative Director across the Trinity ecosystem. She builds the visual and audience-facing systems through which the companies are recognized, understood, and remembered.

CREATIVE AUTHORITY	BOUNDARY
Brand architecture, logos, color, typography, photography, campaign design, publication design, apparel presentation.	Creative authority cannot change product facts, founder history, technical results, certification status, or financial commitments.
Women's apparel creative development with Cristina; men's collection execution with Abel and Gabriel.	Digital mockups do not replace physical samples, production proofs, fit review, or cost approval.
Laboratory identity, forms, service pages, report visual templates, capability materials.	The laboratory cannot appear accredited before formal accreditation is granted for the applicable scope.

Brand Architecture

Trinity should operate as a branded family with clear legal attribution: Trinity Peptides LLC founded by Gabriel; Trinity & Co. founded by Abel Ortiz and co-founded by Cristina Tello; Trinity Analytical Laboratory as a division of Trinity & Co., founded and operated by Abel.

VISUAL CLAIMS RULE
A claim can be written, pictured, suggested, or emotionally implied. All four forms require control.

“Creative presentation should reveal the strength of the organization, not create an appearance stronger than the organization itself.”

CHAPTER NINE

How the Trinity Leadership Team Makes Decisions



Authority, consultation, evidence, documentation, and
conflict control

Trinity needs a decision system that protects speed without allowing important commitments to become informal, undocumented, or contradictory.

DECISION AREA	FINAL AUTHORITY
Trinity Peptides LLC product operations	Gabriel.
Trinity & Co. strategy, publishing, technical systems, and laboratory	Abel.
Project schedules and implementation within approved scope	Cristina.
Brand and creative execution within approved facts and budget	Mercedes.
Laboratory analytical conclusion and report release	Abel or authorized qualified laboratory personnel.
Material cross-company commitments	Gabriel and Abel jointly for the affected entities.

Four Decision Levels

- **Routine operating:** within approved procedures and budgets.
- **Department:** affects one function within an approved strategy.
- **Executive:** materially affects finance, strategy, customers, or multiple departments.
- **Reserved:** affects ownership, major debt, accreditation, safety, legal exposure, company structure, or scientific integrity.

TECHNICAL INDEPENDENCE

Scientific disagreement is resolved through methods, raw data, standards, quality-control results, calculations, competence, and independent review - not founder preference or commercial pressure.

“Trinity will grow because the right person makes each decision, the right people contribute, and the organization records what it has chosen to do.

PART III

Building the Trinity Operating System

The systems that convert approved direction into controlled execution, financial clarity, physical traceability, and reliable communication.

CHAPTER TEN

From Ideas to Assigned Projects



The disciplined path from possibility to authorized
commitment

Trinity will never suffer from a shortage of ideas. The operating risk is allowing every suggestion to become an active commitment.

PIPELINE STATE	MEANING
Captured	The idea is recorded; no work is approved.
Evaluating	Leadership is gathering information.
Approved for planning	A formal plan may be developed within limited boundaries.
Active project	Scope, owner, budget, milestones, and decision gates are approved.
Closed	Completed, canceled, deferred, merged, or transferred to operations.

Evaluation Questions

1. What problem is being solved?
2. Which company should own it?
3. Who is the customer?
4. Does it fit the strategy?
5. Can Trinity deliver it competently?
6. What are the financial and cash requirements?
7. What risks and assumptions must be tested?
8. Who sponsors, owns, manages, and approves it?

“ Ideas create possibility. Projects create obligations.

WORK-IN-PROGRESS LIMIT

Starting fewer major projects can allow Trinity to complete more projects. The portfolio should be limited by real leadership, cash, technical, and creative capacity.

CHAPTER ELEVEN

The Trinity Project- Management System



Planning, tracking, escalating, changing, and closing
work

The project-management system creates one operating language across two companies while preserving separate entity records.

CORE RECORD	PURPOSE
Master project register	One view of all major commitments.
Project charter	Defines company, sponsor, owner, scope, budget, milestones, risks, and approval.
Action register	Tracks assigned work and evidence of completion.
Decision log	Preserves authority, conditions, and implementation.
Risk and issue register	Makes uncertainty and active problems visible.
Change log	Protects the approved scope, schedule, budget, and quality baseline.
Closure report	Documents acceptance, cost, lessons, and operational ownership.

Project Health

HEALTH	MEANING
Green	Within approved boundaries.
Yellow	Material risk requires attention.
Red	Objective, cost, quality, schedule, or compliance is seriously threatened.
Paused	Work formally stopped by decision.

SYSTEM RULE

No major project remains active without a defined company, accountable owner, approved scope, visible milestone, current status, and next decision.

Laboratory development uses the same project system for facility, equipment, staffing, quality-system, method, and accreditation workstreams, while technical decisions remain controlled by Abel and qualified laboratory personnel.

CHAPTER TWELVE

Accounting and Financial Control



Protecting cash, understanding profit, and preserving
entity separation

Connected companies may support one another, but their financial records must not become interchangeable.

FINANCIAL CONTROL	REQUIRED PRACTICE
Separate books and bank accounts	Each legal entity records its own revenue, expenses, assets, liabilities, merchant activity, and taxes.
Laboratory departmental reporting	Trinity Analytical Laboratory is tracked within Trinity & Co. by revenue, direct cost, equipment, staff, accreditation, and service line.
Inventory accounting	Trinity Peptides LLC tracks quantity, lot, landed cost, held value, loss, sales, and remaining stock.
Intercompany transactions	Services, testing, shared costs, licenses, and reimbursements are documented and reasonably priced.
Cash forecasting	A rolling 13-week cash view and higher-level annual forecast protect working capital.
Professional support	Bookkeepers, CPAs, tax advisers, attorneys, and specialists control licensed advice.

“

Cash is different from profit, and sales are different from retained value.

True Cost

Product, publication, apparel, laboratory, and contract prices must include more than the visible supplier or production cost. They must account for freight, testing, packaging, fees, labor, quality, returns, software, insurance, equipment, professional services, taxes, and working-capital risk.

MAJOR COMMITMENT GATE

Which company pays? What is the lifetime cost? What cash is required and when? What capability or return is expected? What happens if revenue is delayed?

CHAPTER THIRTEEN

Inventory, Vendors, Equipment and Fulfillment



Controlling the physical systems behind the ecosystem

Trinity cannot control quality, profit, or fulfillment unless it can control the identity, status, location, ownership, and movement of products, samples, equipment, and records.

SYSTEM	PRIMARY AUTHORITY
Trinity Peptides LLC suppliers, purchasing, inventory, packaging, fulfillment	Gabriel.
Laboratory samples, instruments, methods, data, technical reports, quality system	Abel and authorized laboratory personnel.
Implementation schedules, vendor follow-up, document tracking, corrective-action deadlines	Cristina.
Labels, packaging artwork, product photography, public presentation	Mercedes within approved facts.

Lot and Sample Traceability

- Every lot connects supplier, manufacturer when known, COA, receipt, quantity, test report, status, customers, complaints, and disposition.
- New product enters quarantine until required review is complete.
- Released, held, rejected, returned, retained, and disposed statuses remain visible physically and electronically.
- Laboratory chain of custody identifies who selected, transferred, received, tested, reviewed, and disposed of the sample.
- A submitted sample is not automatically representative of an entire lot unless the sampling plan supports that conclusion.

NO RESULT SHOPPING
When laboratories disagree, Trinity investigates methods, standards, samples, calculations, and quality controls. It does not simply select the most favorable number.

Laboratory equipment belongs to Trinity & Co. and is selected from a user-requirement specification, total cost of ownership, facility needs, service availability, software/data controls, qualification, calibration, maintenance, and qualified-user requirements.

CHAPTER FOURTEEN

Publishing, Marketing, Catalogs and Social Media



One coordinated system for education, authority,
customer communication, and growth

Publishing, marketing, catalogs, websites, and social media form the public operating system through which Trinity educates, sells, recruits, develops authority, and preserves its history.

PUBLIC FUNCTION	CONTROL
Publishing	Abel leads editorial architecture; Cristina coordinates; Mercedes designs; relevant founders and specialists approve facts.
Trinity Peptides LLC catalog	Gabriel controls operational facts; Abel reviews technical language; Mercedes designs; Cristina manages version and channel updates.
Laboratory communication	Abel and qualified personnel control service, method, limitation, report, accreditation, and quality statements.
Marketing	Business objective and operational readiness precede creative launch.
Social media	Accounts have entity ownership, administrators, approval pathways, escalation rules, and archived content.

The Source-of-Truth Rule

Product names and configurations come from the product master. Prices come from the approved pricing file. Availability comes from inventory. Founder titles come from the governance record. Laboratory status comes from controlled quality records. Government status comes from verified registrations or certifications.

PUBLIC COMMUNICATION TEST

Which company is speaking? Who owns the facts? Who reviewed the claims? Can operations fulfill the promise? Where is the approved version stored?

“ Every public statement becomes part of Trinity’s permanent reputation, even when it was intended to be temporary content.

CHAPTER FIFTEEN

The Trinity Responsibility Matrix



The authoritative first-half framework for
accountability, execution, consultation, and information

The first half of this volume has defined the mission, the companies, the founders, the department leaders, the decision system, and the operating controls. Chapter Fifteen converts that architecture into one authoritative responsibility matrix.

A responsibility matrix does not remove judgment. It prevents the organization from repeatedly renegotiating basic authority every time a project begins. It tells employees, vendors, customers, advisers, and future leaders who is accountable, who performs the work, who must be consulted, and who must be informed.

“The matrix is not a chart of importance. It is a chart of obligation.

The Four Responsibility Designations

DESIGNATION	MEANING
Accountable	Owns the final result and has the authority required to accept, reject, stop, or redirect the work.
Responsible	Performs or directly manages the work required to produce the result.
Consulted	Provides expertise or information before the decision or deliverable is completed.
Informed	Receives the decision, status, or result because later work depends upon it.

One person should normally be accountable for each result. Several people may be responsible or consulted. Shared accountability should be reserved for true cross-company commitments where both legal entities are materially bound.

The Leadership Anchors

LEADER	OFFICIAL ROLE	NON-TRANSFERABLE ANCHOR
Gabriel	Founder, Trinity Peptides LLC	Founder authority over Trinity Peptides LLC product operations, suppliers, purchasing, inventory, packaging, labeling, fulfillment, and operational use of quality results.
Abel Ortiz	Founder, Trinity & Co.; Founder and Operator, Trinity Analytical Laboratory	Founder authority over Trinity & Co.; technical and operational authority over the laboratory, publishing, strategic development, financial systems, and government-readiness work.

LEADER	OFFICIAL ROLE	NON-TRANSFERABLE ANCHOR
Cristina Tello	Co-Founder, Trinity & Co.; Project Manager for both companies	Authority over the approved project-management process, schedules, action tracking, communication, escalation, customer-experience coordination, and implementation visibility.
Mercedes	Brand, Marketing and Creative Director	Authority over brand architecture, visual identity, campaign creative, publication design, apparel presentation, photography, and creative consistency.

Leadership rule. Collaboration may broaden the information used in a decision. It does not silently transfer final authority. Support from Abel does not make him Founder of Trinity Peptides LLC. Project management by Cristina does not make her the product, scientific, or financial approver. Creative authority by Mercedes does not allow visual presentation to change facts. Product ownership by Gabriel does not allow Trinity Peptides LLC to alter a laboratory conclusion.

Corporate Governance and Legal-Entity Matrix

FUNCTION	ACCOUNTABLE	RESPONSIBLE	CONSULTED	INFORMED
Trinity Peptides LLC company strategy	Gabriel	Gabriel and assigned team	Abel, Cristina, Mercedes, professional advisers	Affected personnel
Trinity & Co. company strategy	Abel	Abel and assigned team	Cristina, Mercedes, Gabriel when connected	Affected personnel
Company ownership or structural changes	Founder(s) of affected entity	Authorized legal and financial team	Attorney, CPA, affected leaders	Personnel as appropriate
Intercompany agreement	Gabriel and Abel jointly	Authorized representatives	Attorney, CPA, Cristina, relevant department leads	Affected teams
Founder-title and company-history record	Founder of the entity and person described	Cristina maintains record; Mercedes applies it	Legal adviser when needed	All public-content owners

Trinity Peptides LLC Product Operations Matrix

FUNCTION	ACCOUNTABLE	RESPONSIBLE	CONSULTED	INFORMED
Product addition or removal	Gabriel	Gabriel and product operations	Abel technical/financial; Cristina project; Mercedes brand	Website, fulfillment, customer support
Supplier approval and purchasing	Gabriel	Gabriel or authorized buyer	Abel for technical or material financial review; Cristina tracks	Accounting, inventory personnel

FUNCTION	ACCOUNTABLE	RESPONSIBLE	CONSULTED	INFORMED
Inventory receipt, quarantine, release, hold, rejection	Gabriel	Authorized inventory personnel	Abel/laboratory for technical evidence; Cristina coordinates	Fulfillment, accounting, website
Packaging and label facts	Gabriel	Product operations	Abel technical; Mercedes creative; Cristina version control	Fulfillment and customer support
Fulfillment and shipping	Gabriel	Authorized fulfillment personnel	Cristina customer process; Mercedes packaging; Abel systems/financial	Customer support, accounting
Supplier-quality action	Gabriel	Gabriel and assigned quality coordinator	Abel technical explanation; Cristina corrective-action tracking	Accounting, inventory, website as needed

Trinity Analytical Laboratory Matrix

FUNCTION	ACCOUNTABLE	RESPONSIBLE	CONSULTED	INFORMED
Laboratory ownership, strategy, and service scope	Abel	Abel and qualified laboratory management	Financial, quality, legal, accreditation, and market specialists	Cristina, Mercedes, Gabriel when relevant
Facility and instrument selection	Abel	Abel and qualified technical personnel	Vendors, engineers, finance, Cristina, Gabriel for product-quality needs	Mercedes for public presentation
Method development, validation, verification	Abel or authorized technical manager	Qualified analysts	Quality personnel, external specialists	Cristina for milestones; Gabriel for relevant service readiness
Sample receipt and chain of custody	Authorized laboratory manager under Abel	Qualified sample-control personnel	Customer and quality personnel	Submitting customer
Analytical conclusion and report release	Abel or authorized qualified signatory	Qualified analyst and reviewer	Quality personnel or independent reviewer	Customer; Gabriel only for Trinity Peptides LLC samples
ISO/IEC 17025 accreditation development	Abel	Abel, quality personnel, qualified consultants	Accreditation body, technical staff, Cristina	Mercedes and customers through approved status language
GMP/cGMP professional development	Abel	Abel and assigned personnel	Qualified GMP professionals, ASQ resources, legal/regulatory advisers	Cristina for training records; public only through accurate wording advisers
Laboratory impartiality and conflict control	Abel	Quality management and authorized technical staff	Legal/quality advisers	Affected customers and leaders as required

LABORATORY NON-NEGOTIABLE

Commercial ownership, family relationships, inventory value, launch timing, or customer pressure cannot change the method, raw data, integration, result, technical conclusion, or authorized report language.

Gabriel's Laboratory-Oversight Development Matrix

DEVELOPMENT AREA	TEACHER / AUTHORITY	GABRIEL LEARNS TO OVERSEE	BOUNDARY
Chain of custody and lot linkage	Abel and qualified laboratory personnel	Correct product, lot, sample, report, and inventory connection	Does not independently redesign laboratory sample-control rules
Identity and purity reports	Abel	Meaning, limitations, supplier comparison, escalation	Does not alter the scientific conclusion
Inventory holds and supplier action	Gabriel with Abel's technical guidance	Operational containment, vendor inquiry, retesting, disposition	Laboratory retains technical-report authority
Future quality-support personnel	Gabriel, trained by Abel	Assignment, workflow, document review, follow-up, performance	Technical authority requires documented competence
Quality trends	Abel and Gabriel collaboratively	Recurring supplier failures, lot risks, complaint patterns, decision thresholds	Trend review does not replace method-specific investigation

Financial and Accounting Matrix

FUNCTION	ACCOUNTABLE	RESPONSIBLE	CONSULTED	INFORMED
Trinity Peptides LLC financial commitments	Gabriel	Authorized buyer/financial personnel	Abel analysis; CPA/bookkeeper; Cristina project tracking	Affected operational leaders
Trinity & Co. financial commitments	Abel	Authorized financial personnel	CPA/bookkeeper; Cristina; relevant department lead	Affected leaders
Laboratory startup and operating budget	Abel	Abel and assigned financial/laboratory team	Qualified technical personnel, CPA, vendors, Cristina	Gabriel where shared quality needs affect planning
Monthly close and reporting	Founder of entity	Bookkeeper/accounting personnel	Abel coordination, CPA review as needed	Leadership team

FUNCTION	ACCOUNTABLE	RESPONSIBLE	CONSULTED	INFORMED
Intercompany pricing and allocation	Gabriel and Abel	Accounting personnel	CPA, attorney, relevant managers	Cristina and affected project owners
Fraud prevention and access control	Founder of entity	Authorized financial administrator	CPA, cybersecurity, bank, Cristina	Leadership according to need

Project-Management Matrix

FUNCTION	ACCOUNTABLE	RESPONSIBLE	CONSULTED	INFORMED
Master project system	Cristina	Cristina	Abel, Gabriel, Mercedes, future project managers	All project contributors
Project approval	Founder / sponsor of responsible entity	Project sponsor	Cristina, finance, technical, creative, legal as needed	Assigned team
Project charter and schedule	Project owner	Cristina or assigned project manager	Sponsor and contributors	Leadership dashboard
Scope change	Project sponsor / paying-company founder	Cristina documents and updates	Affected leads and advisers	All affected contributors
Risk and issue escalation	Accountable project owner	Cristina and discovering person	Relevant expert and founder	Affected teams
Project closure	Project sponsor	Cristina	Deliverable owners, finance, operations	Leadership and continuing owner

Publishing, Education and Intellectual Property Matrix

FUNCTION	ACCOUNTABLE	RESPONSIBLE	CONSULTED	INFORMED
Publishing roadmap	Abel	Abel and publishing team	Cristina, Mercedes, Gabriel for relevant company content	Leadership
Manuscript architecture and editorial approval	Abel	Authors and editors	Technical reviewers, Cristina, person described	Mercedes for design
Publication design and production files	Mercedes within Abel's publishing approval	Mercedes and production vendors	Abel, Cristina, printer	Contributors
Trinity Peptides LLC operational content	Gabriel	Product-content owner	Abel technical; Cristina coordinates; Mercedes designs	Customer support and website

FUNCTION	ACCOUNTABLE	RESPONSIBLE	CONSULTED	INFORMED
Copyright, licensing, releases	Abel for Trinity & Co. assets; Gabriel for Trinity Peptides LLC assets	Authorized administrator	Attorney, contributors, photographers, designers	Project team

Brand, Marketing, Catalog and Social Matrix

FUNCTION	ACCOUNTABLE	RESPONSIBLE	CONSULTED	INFORMED
Brand standards	Mercedes	Mercedes and creative team	Abel, Gabriel, Cristina	All content creators
Campaign business objective and budget	Founder of responsible entity	Abel strategy/financial; relevant business owner	Mercedes, Cristina, operations	Customer-support and fulfillment teams
Campaign creative	Mercedes	Creative team	Content owner, Cristina, technical reviewer	Responsible founder
Product catalog facts	Gabriel	Product operations/content owner	Abel technical; Cristina version; Mercedes design	Website and fulfillment
Laboratory service communication	Abel	Authorized laboratory/content personnel	Mercedes, Cristina, quality/legal reviewers	Sales and customer support
Social account administration and calendar	Cristina	Cristina and authorized social personnel	Mercedes, content owners, cybersecurity	Leadership
High-risk public correction	Responsible founder	Cristina coordinates; Mercedes updates	Technical/legal/quality advisers	Affected customers or public

Apparel Matrix

FUNCTION	ACCOUNTABLE	RESPONSIBLE	CONSULTED	INFORMED
Men's collection direction	Abel and Gabriel within the paying/owning company decision	Mercedes creative; Cristina project coordination	Vendors, target customers, finance	Website and fulfillment
Women's collection direction	Cristina and Mercedes within Abel's Trinity & Co. approval	Cristina operational; Mercedes creative	Customers, vendors, finance	Website and fulfillment
Samples and production proof	Responsible collection lead	Cristina and Mercedes	Abel/Gabriel, vendor	Accounting and launch team
Production-order approval	Founder of paying entity	Authorized buyer	Collection leads, finance, Cristina	Fulfillment and marketing

FUNCTION	ACCOUNTABLE	RESPONSIBLE	CONSULTED	INFORMED
Inventory and returns	Founder of owning entity	Authorized inventory/customer personnel	Cristina, finance, Mercedes for quality presentation	Marketing

Customer Experience, Community and Veteran Mission Matrix

FUNCTION	ACCOUNTABLE	RESPONSIBLE	CONSULTED	INFORMED
Customer-experience system	Cristina within company policy	Customer-support and operations personnel	Gabriel/Abel by company; Mercedes for communication	Leadership
Routine complaint resolution	Operational owner	Authorized customer-support personnel	Cristina; technical/quality personnel as needed	Founder according to threshold
Serious product or laboratory complaint	Responsible founder / Abel for laboratory	Assigned investigation team	Legal, quality, insurance, Cristina	Affected parties according to approved plan
Veteran and caregiver initiatives	Abel and Cristina for Trinity & Co.	Program team	Veterans, caregivers, partners, legal/privacy advisers, Mercedes	Leadership and participants
Community storytelling	Person providing consent and responsible program leader	Mercedes creative; Cristina coordination	Legal/privacy and person depicted	Audience

Government-Contracting Matrix

FUNCTION	ACCOUNTABLE	RESPONSIBLE	CONSULTED	INFORMED
Bid / no-bid decision	Authorized founder of bidding entity	Abel and opportunity team	Operations, finance, legal, Cristina, Mercedes	Leadership
Entity registration and representations	Authorized founder	Authorized administrator	Attorney, CPA, contracting specialist	Proposal team
Capability statement and proposal substance	Authorized founder	Abel and subject-matter owners	Gabriel for Trinity Peptides LLC; laboratory staff; finance	Cristina and Mercedes
Proposal schedule and submission control	Authorized founder	Cristina	All proposal contributors	Leadership
Proposal visual presentation	Mercedes	Creative team	Content owners, Cristina	Authorized founder

FUNCTION	ACCOUNTABLE	RESPONSIBLE	CONSULTED	INFORMED
Contract performance	Authorized founder / program owner	Assigned program team	Finance, legal, quality, cybersecurity, Cristina	Customer and leadership

Technology, Cybersecurity and Data Matrix

FUNCTION	ACCOUNTABLE	RESPONSIBLE	CONSULTED	INFORMED
Business-system architecture	Abel	Authorized technical personnel	Cristina, Gabriel, Mercedes, vendors	Users
Website content accuracy	Content owner / responsible founder	Authorized publisher	Abel technical, Mercedes creative, Cristina verification	Customer support
Account access and recovery	Founder of entity	Authorized system administrator	Cybersecurity specialist, Cristina	Affected leaders
Laboratory data integrity	Abel	Qualified laboratory and IT personnel	Quality, cybersecurity, vendors	Authorized customers and leaders
Incident response	Founder / Abel for laboratory	Assigned technical and response team	Legal, insurance, Cristina, Mercedes for communication	Affected parties

Hiring, Training and Delegation Matrix

FUNCTION	ACCOUNTABLE	RESPONSIBLE	CONSULTED	INFORMED
Hiring approval	Founder of employing entity	Authorized hiring manager	Cristina, department lead, legal/HR, finance	Leadership
Role description and authority	Founder / department accountable leader	Hiring manager and Cristina	Legal/HR, technical or creative lead	Employee
Laboratory competence and technical authorization	Abel or authorized laboratory manager	Qualified trainers and assessors	Quality personnel	Employee and project team
Product-operations training	Gabriel	Authorized trainers	Abel for laboratory/QC interfaces; Cristina for records	Employee
Creative-system training	Mercedes	Creative team	Cristina	Content creators
Delegated-authority register	Founder of entity	Cristina or authorized administrator	Legal/finance/department lead	Delegate and affected staff

Reserved Decisions

The following matters cannot be delegated through ordinary project convenience:

- Changes to company ownership, founder titles, or legal structure.
- Major debt, guarantees, sale of substantial assets, or transfer of control.
- Material intercompany contracts or shared-asset commitments.
- Claims of accreditation, certification, government status, or regulatory approval.
- Laboratory analytical conclusions, report release, scope representation, or technical-authority assignments.
- Serious product-quality, safety, legal, fraud, privacy, cybersecurity, or contract responses.
- Major hiring, termination, settlement, litigation, or government-contract commitments.
- Public statements that materially affect the reputation or obligations of both companies.

Escalation Matrix

ISSUE	FIRST ESCALATION	NEXT REVIEW
Trinity Peptides LLC product, supplier, inventory, packaging, or fulfillment	Gabriel	Abel for technical/financial; legal/quality as needed
Trinity & Co. strategic, financial, publishing, service, or contracting issue	Abel	Professional adviser or affected leader
Laboratory technical, quality, data, or report issue	Abel and authorized laboratory personnel	Independent technical/quality/legal review
Project delay, dependency, conflicting instructions, or undocumented scope	Cristina	Responsible founder or project sponsor
Creative, production, brand, or visual-claim issue	Mercedes	Content owner and responsible founder
Cross-company obligation or conflict	Gabriel and Abel	Attorney, CPA, technical, or other independent adviser

The Future-Employee Rule

As Trinity hires analysts, quality personnel, fulfillment staff, customer-support personnel, project managers, designers, accountants, and contracting professionals, authority must expand through documented competence and delegation - not through informal assumptions.

COMPETENCE BEFORE AUTHORITY

Trust, family relationship, loyalty, or management title does not replace education, training, demonstrated competence, authorization, and continuing review where technical or controlled work is involved.

The One-Page Executive Matrix

DOMAIN	FINAL ACCOUNTABILITY
Trinity Peptides LLC	Gabriel - Founder and product-operations authority.
Trinity & Co.	Abel Ortiz - Founder and strategic/business authority.
Trinity Analytical Laboratory	Abel Ortiz - Founder and Operator; technical authority delegated only to qualified authorized personnel.
Cross-company project management	Cristina Tello - system administration, schedules, communication, escalation, and implementation visibility.
Brand, marketing, design and visual presentation	Mercedes - creative authority within approved facts, budgets, and capability.
Material shared commitment	Gabriel and Abel for their affected entities, with documented professional review where appropriate.

Monthly Leadership Attestation

At the monthly leadership review, each leader should be able to state:

- **Gabriel:** I know the current product, supplier, inventory, fulfillment, hold, and quality-application status of Trinity Peptides LLC.
- **Abel:** I know the strategic, financial, publishing, technical, laboratory, accreditation-development, and contracting status of Trinity & Co.
- **Cristina:** I know which projects are active, who owns them, what is due, what is blocked, what changed, and what must be escalated.
- **Mercedes:** I know which public and creative assets are approved, current, accurate, production-ready, and consistent with the brand system.

The Responsibility Matrix as a Living Control

The matrix should be reviewed when:

- A new employee or manager is hired.
- A new division, service, or legal entity is created.
- The laboratory adds a method, instrument, accredited scope, or authorized signatory.
- A leader delegates authority.
- A government contract introduces new obligations.
- A serious error reveals that responsibility was unclear.
- The companies begin sharing personnel, facilities, equipment, or intellectual property in a new way.

Revisions must identify the effective date, approving authority, affected roles, training or communication required, and superseded version.

Chapter Conclusion

The Trinity responsibility matrix completes the first-half operating constitution.

It confirms that Gabriel is Founder of Trinity Peptides LLC and holds final accountability for its product operations. It confirms that Abel Ortiz is Founder of Trinity & Co. and Founder and Operator of Trinity Analytical Laboratory. It confirms that Cristina Tello is Co-Founder of Trinity & Co. and Project Manager for both companies. It confirms that Mercedes is Brand, Marketing and Creative Director.

It also establishes the boundaries that protect those roles:

- Product authority cannot change laboratory science.
- Technical authority cannot erase product-company founder recognition.
- Project authority cannot replace founder or specialist approval.
- Creative authority cannot change facts.
- Shared mission cannot erase legal-entity separation.
- Growth cannot outrun competence, evidence, cash, or control.

“

Trinity becomes an institution when every person can answer not only what they are allowed to do, but what they are responsible for protecting.

First-Half Review Complete

The first half now establishes the governing architecture required before Trinity expands into services, certifications, government opportunities, veteran programs, and long-term growth.

COMPLETED FOUNDATION	STATUS
Distinct company structure and founder recognition	Established
Trinity Analytical Laboratory ownership and authority	Corrected and established under Trinity & Co. and Abel Ortiz
Leadership responsibilities	Defined
Product portfolio governance	Mapped across twelve research categories
Decision, project, financial, inventory, equipment, and communication systems	Established
Responsibility matrix	Completed

Review decision: ☐ Approve structure ☐ Approve with corrections ☐ Revise before Part IV

Abel Ortiz / Date _____

Gabriel / Date _____

Cristina Tello / Date _____

Mercedes / Date _____

Development of Part IV should begin only after the leadership, laboratory, and responsibility structure in this review proof is accepted.



THE TRINITY FOUNDER'S COLLECTION

Distinct companies. One mission. A shared standard.

Trinity Peptides LLC • Founded by Gabriel

Trinity & Co. • Founded by Abel Ortiz • Co-Founded by Cristina Tello

Trinity Analytical Laboratory • A Division of Trinity & Co. • Founded and Operated by Abel Ortiz

Brand, Marketing and Creative Direction • Mercedes